Oncology ESMO26: Taiho Oncology on improving the lives of patients wi... Dr Harold Keer, chief medical officer at Taiho Oncology, discusses the Phase 2 REZILIENT2 trial data presented at ESMO26 and the NSCLC setting.
News Roche joins the oral SERD club as FDA clears Wilserdly Roche is the latest drugmaker to bring an oral SERD drug for breast cancer to the US market, after getting FDA approval for its Wilserdly product.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.